High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
(NASDAQ:BIIB),(NASDAQ:IONS), Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1 Final European Commission decision expected in January 2026 SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, […]